Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Chem Res Toxicol ; 12(11): 1098-109, 1999 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-10563836

RESUMEN

The DNA repair enzyme, N-methylpurine DNA glyclosylase (MPG), is overexpressed in breast cancer as compared with its expression in normal breast epithelial cells. In an effort to determine the mechanism responsible for this difference in expression, we studied rates and regulation of transcription of the MPG gene in normal (HMEC), spontaneously immortalized (MCF10A), and malignant (T47D) mammary epithelial cells. Steady state levels of MPG mRNA are 3-4-fold greater in T47D cells than in MCF10A cells. Nuclear "run-off" transcription measurements revealed MPG transcription rates to be approximately 3-fold greater in the tumor cells than in normal cells. Characterization of the MPG promoter by deletion analysis and transient transfection experiments revealed that all basal promoter activity resided between nucleotides -227 and -81 upstream from the ATG translation start site. Constructs containing this region were expressed at 4-fold greater levels when transfected into malignant T47D cells (56 x baseline) than in MCF10A cells (14 x baseline). Computer database analysis of the region of nucleotides -227 to -81 revealed multiple overlapping Sp1 consensus binding sites and two overlapping consensus AP-2 binding sites located between bases -181 and -169. Electrophoretic mobility shift assays indicated that while Sp1 bound this region of the promoter, nuclear extracts from both cell types contained equal Sp1 binding activity. In contrast, AP-2 binding activity was significantly greater in T47D cells, and Western blots confirmed increased AP-2 protein levels in these cells. Cotransfection into MCF10A cells of the MPG promoter construct and an AP-2 expression plasmid increased MPG promoter activity 2.1-fold. Cotransfection of a dominant negative mutant of AP-2 into T47D cells reduced the extent of MPG promoter-driven transcription by 50%. To investigate the functional significance of the two overlapping AP-2 consensus binding sites, each site was mutated separately. Mutation of the upstream site decreased promoter activity by 15%, but mutation of the downstream site decreased promoter activity by 45% and abolished AP-2 binding to the promoter sequence. These data suggest that AP-2 is important in regulating MPG expression in breast cancer cells, and that the increased amount of AP-2 in these cells plays a major role in directing the increased expression of MPG.


Asunto(s)
Neoplasias de la Mama/enzimología , Mama/enzimología , Reparación del ADN/fisiología , Proteínas de Unión al ADN/fisiología , Células Epiteliales/enzimología , N-Glicosil Hidrolasas/biosíntesis , Factores de Transcripción/fisiología , Western Blotting , Mama/patología , Neoplasias de la Mama/patología , ADN Glicosilasas , Femenino , Radicales Libres , Humanos , Indicadores y Reactivos , Cinética , Luciferasas/química , Mutagénesis Sitio-Dirigida , Regiones Promotoras Genéticas/genética , Factor de Transcripción AP-2 , Transfección
2.
Chest ; 115(4): 1175-80, 1999 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-10208225

RESUMEN

BACKGROUND: beta-blockade controls the ventricular response to exercise in chronic atrial fibrillation (AF), but the effects of beta-blockers on exercise capacity in AF have been debated. METHODS: Twelve men with AF (65+/-8 years) participated in a randomized, double-blind, placebo-controlled study of betaxolol (20 mg daily). Patients underwent maximal exercise testing with ventilatory gas exchange analysis, and a separate, submaximal test (50% of maximum) during which cardiac output was measured by a CO2 rebreathing technique. RESULTS: After betaxolol therapy, heart rate was reduced both at rest (92+/-27 vs 62+/-12 beats/min; p < 0.001) and at peak exercise (173+/-22 vs 116+/-24 beats/min; p < 0.001). Maximal oxygen uptake (VO2) was reduced by 19% after betaxolol (21.8+/-5.3 with placebo vs 17.6+/-5.1 mL/kg/min with betaxolol; p < 0.05), with similar reductions observed for maximal exercise time, minute ventilation, and CO2 production. VO2 was reduced by a similar extent (19%) at the ventilatory threshold. Submaximal cardiac output was reduced by 15% during betaxolol therapy (12.9+/-2.3 vs 10.9+/-1.3 L/min; p < 0.05), and stroke volume was higher (88.0+/-21 vs 105.6+/-19 mL/beat; p < 0.05). CONCLUSION: Betaxolol therapy in patients with AF effectively controlled the ventricular rate at rest and during exercise, but also caused considerable reductions in maximal VO2 and cardiac output during exercise. The observed increase in stroke volume could not adequately compensate for reduced heart rate to maintain VO2 during exercise.


Asunto(s)
Antagonistas Adrenérgicos beta/uso terapéutico , Fibrilación Atrial/fisiopatología , Betaxolol/uso terapéutico , Prueba de Esfuerzo , Hemodinámica/efectos de los fármacos , Intercambio Gaseoso Pulmonar/efectos de los fármacos , Anciano , Fibrilación Atrial/tratamiento farmacológico , Gasto Cardíaco/efectos de los fármacos , Enfermedad Crónica , Estudios Cruzados , Método Doble Ciego , Tolerancia al Ejercicio , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Volumen Sistólico/efectos de los fármacos
3.
Genomics ; 29(2): 383-9, 1995 Sep 20.
Artículo en Inglés | MEDLINE | ID: mdl-8666385

RESUMEN

We isolated expressed sequence tags (ESTs) on the long arm of chromosome 21. The ESTs were mapped by PCR using a monochromosomal somatic-cell mapping panel. Of a total of 55 cDNAs, 30 mapped back uniquely to chromosome 21, 7 mapped back to other chromosomes including chromosome 21, 8 mapped back to chromosomes other than 21, and 10 could not be assigned using this methodology. The 30 chromosome 21-specific markers so isolated represent useful EST markers. A rapid PCR-based method was used to delineate the expression pattern of these 30 pairs in different tissues.


Asunto(s)
Cromosomas Humanos Par 21 , Lugares Marcados de Secuencia , Animales , Secuencia de Bases , Mapeo Cromosómico , Cartilla de ADN , ADN Complementario , Marcadores Genéticos , Humanos , Células Híbridas , Datos de Secuencia Molecular , Reacción en Cadena de la Polimerasa/métodos
4.
Prim Care ; 21(3): 459-74, 1994 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-9132753

RESUMEN

A growing number of physicians are performing exercise tests in their offices for the purposes of diagnosing cardiopulmonary disease and assessing exercise capacity in patients with heart disease. Methodology of testing is important in making the most effective use of the information gathered from the test. Selecting an approach that fits the objectives of the test and the individual being tested is essential for accurate and reproducible results. This article discusses the various exercise protocols and equipment used in exercise testing.


Asunto(s)
Prueba de Esfuerzo , Medicina Deportiva , Prueba de Esfuerzo/instrumentación , Prueba de Esfuerzo/métodos , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA